News Search Results
Feb 24, 2026, 07:00 ET Bio-Techne to Present at Upcoming Investor Conferences
https://investors.bio-techne.com/ir-calendar.About Bio-TechneBio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into
More news about: Bio-Techne Corporation
Feb 17, 2026, 11:42 ET Growth Factors Market to Reach US$ 3.7 Bn by 2033, Expands Amid Rising Regenerative Medicine and Biopharmaceutical Innovation - Persistence Market Research
regulatory requirements, reinforcing the need for advanced solutions.Key Highlight: Bio-Techne Launches Next Generation Cytokines & Growth Factors• In 2025, Bio-Techne introduced its next generation line of cytokines and growth factors, expanding its portfolio of
More news about: Persistence Market Research Pvt. Ltd.
Feb 16, 2026, 06:30 ET Bio-Techne's Ella Platform Achieves CE-IVD Marking Expanding Access to Rapid, Cartridge‑Based Immunoassays for European Clinical Laboratories
reliability for clinical use.About Bio-Techne: Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into
More news about: Bio-Techne Corporation
Feb 11, 2026, 09:00 ET Bio-Techne Announces Changes to its Leadership Team
Bio-Techne's next phase of growth." About Bio-Techne Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into
More news about: Bio-Techne Corporation
Feb 04, 2026, 06:30 ET Bio-Techne Declares Dividend
considered by the Board of Directors on a quarterly basis.Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological
More news about: Bio-Techne Corporation
Feb 04, 2026, 06:30 ET Bio-Techne Releases Second Quarter Fiscal 2026 Results
offset by unfavorable product mix.About Bio-TechneBio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into
More news about: Bio-Techne Corporation
Feb 02, 2026, 06:30 ET Bio-Techne Expands 3D Stem Cell and Organoid Culture Portfolio with a Fully Defined Synthetic Alternative
about Cultrex Synthetic Hydrogel.About Bio-Techne Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into
More news about: Bio-Techne Corporation
Jan 28, 2026, 06:30 ET Bio-Techne Launches Simple Plex Ultra-Sensitive Assays on Ella Platform to Enable Femtogram-Level Detection of Neurological Biomarkers
www.bio-techne.com/ultrasensitiveAbout Bio-Techne Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. With hundreds of thousands of products in its portfolio, Bio-Techne generated over $1.2
More news about: Bio-Techne Corporation
Jan 20, 2026, 07:00 ET Bio-Techne to Host Conference Call on February 4, 2026, to Announce Second Quarter Fiscal 2026 Financial Results
CST on Wednesday, March 4, 2026.About Bio-TechneBio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into
More news about: Bio-Techne Corporation
Dec 23, 2025, 07:00 ET Bio-Techne to Present at the 2026 J.P. Morgan Healthcare Conference
https://investors.bio-techne.com/ir-calendar.About Bio-TechneBio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into
More news about: Bio-Techne Corporation
Dec 17, 2025, 13:46 ET ALZpath-Powered Blood Test Enables Landmark Study on Growing Alzheimer's Disease Prevalence
research, diagnosis, treatment, and monitoring. Through licensing agreements with industry leaders – including Beckman Coulter, Roche, Siemens Healthineers, Bio-techne, Alamar Biosciences, and Quanterix, as well as collaborations with world-class laboratories such as Neurocode, ALZpath is expanding access to early
More news about: ALZpath, Inc.
Dec 15, 2025, 08:30 ET ALZpath and Siemens Healthineers Sign Licensing Agreement to Advance Global Access to Blood-Based Alzheimer's Disease Diagnostic Testing
research, diagnosis, treatment, and monitoring. Through licensing agreements with industry leaders – including Siemens Healthineers, Roche, Beckman Coulter, Bio-techne, Alamar Biosciences, and Quanterix, as well as collaborations with world-class laboratories such as Neurocode, ALZpath is expanding access to early
More news about: ALZpath, Inc.
Dec 11, 2025, 10:15 ET Cell Therapy Technologies Market worth $7.91 billion by 2030 | MarketsandMarkets™
KGaA (Germany), Thermo Fisher Scientific Inc. (US), Lonza (Switzerland), Sartorius AG (Germany), Agilent Technologies Inc. (US), Avantor, Inc. (US), Bio-Techne (US), Avantor, Inc. (US), Fresenius SE & Co KGAA (Germany), BD (US), and Corning Incorporated (US) among others.Browse Adjacent Markets:
More news about: MarketsandMarkets
Dec 11, 2025, 06:30 ET Bio-Techne s'associe au Wyss Center Geneva pour accélérer la biologie spatiale en automatisant la multiomique 3D
collaboration avec le Wyss Geneva positionne Bio-Techne comme un leader dans les outils de recherche de nouvelle génération et permet aux scientifiques d'étudier la biologie dans son véritable contexte spatial.À propos de Bio-Techne Bio-Techne Corporation (NASDAQ : TECH) est une société
More news about: Bio-Techne Corporation
Dec 11, 2025, 06:30 ET Bio-Techne Partners with the Wyss Center Geneva to Advance Automated 3D Multiomics Technology and Accelerate Spatial Biology
analytical depth, the collaboration with Wyss Geneva positions Bio-Techne as a leader in next-generation research tools, enabling scientists to study biology in its actual spatial context.About Bio-TechneBio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing
More news about: Bio-Techne Corporation
Dec 11, 2025, 06:30 ET Bio-Techne Partners with the Wyss Center Geneva to Advance Automated 3D Multiomics Technology and Accelerate Spatial Biology
analytical depth, the collaboration with Wyss Geneva positions Bio-Techne as a leader in next-generation research tools, enabling scientists to study biology in its actual spatial context.About Bio-TechneBio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing
More news about: Bio-Techne Corporation
Dec 09, 2025, 06:30 ET Bio-Techne Launches the Enhanced Leo™ System Delivering Advanced Multiplexing and High-Throughput Protein Analysis
fluorescence-based detection capabilities.ABOUT BIO-TECHNE:Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological
More news about: Bio-Techne Corporation
Nov 25, 2025, 07:00 ET Bio-Techne to Present at Upcoming Investor Conferences
https://investors.bio-techne.com/ir-calendar.About Bio-TechneBio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into
More news about: Bio-Techne Corporation
Nov 18, 2025, 06:30 ET Bio-Techne Licenses AI-Designed NovoBody™ Duo Molecules from Monod Bio to Expand Recombinant Protein Portfolio
ABOUT BIO-TECHNE: Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for research and clinical diagnostic communities. Bio-Techne products assist scientific investigations
More news about: Bio-Techne Corporation
Nov 06, 2025, 08:30 ET ALZpath Proprietary pTau217 Antibody Wins BioTech Breakthrough Award for 'Diagnostics Innovation of the Year'
treatment and monitoring. Through licensing agreements with industry leaders – including Beckman Coulter Diagnostics, Roche, Alamar Biosciences, Bio-techne, and Quanterix – ALZpath is accelerating the development of new medicines and expanding access to early diagnosis and monitoring. Additionally, ALZpath
More news about: ALZpath, Inc.
Nov 06, 2025, 07:00 ET Bio-Techne to Present at Upcoming Investor Conferences
About Bio-Techne Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into
More news about: Bio-Techne Corporation
Nov 05, 2025, 06:30 ET BIO-TECHNE DECLARES DIVIDEND
of Directors on a quarterly basis. Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological
More news about: Bio-Techne Corporation
Nov 05, 2025, 06:30 ET Bio-Techne Releases First Quarter Fiscal 2026 Results
About Bio-Techne Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations
More news about: Bio-Techne Corporation
Nov 04, 2025, 09:01 ET AI-Powered Spatial Biology Workflow from Bio-Techne and Nucleai Enables Predictive Biomarker Discovery in Melanoma Patients
also be presented in Poster # 528, alongside additional immuno-oncology research from Bio-Techne and its collaborators. About Bio-Techne Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools
More news about: Bio-Techne Corporation
Nov 03, 2025, 07:00 ET ScaleReady Announces a G-Rex® Grant has been awarded to Sonoma Biotherapeutics
About Bio-Techne Corporation Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne, in partnership with Wilson Wolf,
More news about: Bio-Techne Corporation